Health Economics›Endometrial cancer›Endocrine therapy for advanced recurrent or metastatic disease

Endocrine therapy for advanced recurrent or metastatic disease

Endometrial cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Medroxyprogesterone acetate monotherapy Variant #01	—	R 20 823	28d	—	~6.0 mo	~2	~R 41 646 PFS proxy · indirect	1
Medroxyprogesterone acetate and Tamoxifen Variant #01	—	R 1 761	28d	—	—	~2	~R 3 521 indirect	—
Megestrol and Tamoxifen Variant #01 Partial	—	R 205	21d	—	—	~2	~R 205 indirect	—
Anastrozole monotherapy Variant #01	—	R 159	28d	~13.8 mo	~42.7 mo	~130	~R 20 684 PFS proxy · indirect	12
Tamoxifen monotherapy Variant #01	—	R 137	28d	~7.2 mo	—	~65	~R 8 882 PFS proxy · indirect	1
Megestrol monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

6 of 6 regimens shown